Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amphastar Pharmaceuticals (AMPH) Debt to Equity (2016 - 2026)

Amphastar Pharmaceuticals has reported Debt to Equity over the past 13 years, most recently at $0.77 for Q4 2025.

  • For Q4 2025, Debt to Equity fell 5.85% year-over-year to $0.77; the TTM value through Dec 2025 reached $0.77, down 5.85%, while the annual FY2025 figure was $0.77, 5.85% down from the prior year.
  • Debt to Equity for Q4 2025 was $0.77 at Amphastar Pharmaceuticals, down from $0.78 in the prior quarter.
  • Over five years, Debt to Equity peaked at $1.07 in Q3 2023 and troughed at $0.08 in Q2 2021.
  • A 5-year average of $0.53 and a median of $0.78 in 2025 define the central range for Debt to Equity.
  • Biggest five-year swings in Debt to Equity: skyrocketed 616.19% in 2023 and later decreased 23.58% in 2024.
  • Year by year, Debt to Equity stood at $0.17 in 2021, then decreased by 16.92% to $0.14 in 2022, then skyrocketed by 542.83% to $0.92 in 2023, then fell by 10.93% to $0.82 in 2024, then dropped by 5.85% to $0.77 in 2025.
  • Business Quant data shows Debt to Equity for AMPH at $0.77 in Q4 2025, $0.78 in Q3 2025, and $0.8 in Q2 2025.